Home / Stock ratings / Healthcare Stocks / PFE

Stock rating · Pharmaceutical Preparations

Pfizer Inc. (PFE) Stock Rating & Analysis

As of November 20, 2026, MELANY rates Pfizer Inc. 63 out of 100 (Hold). Its highest factor score is earnings track record at 93, and its lowest is catalyst setup at 36.

MELANY ratingRated 2026-11-20

PFE · composite score

63/100
Hold
Nov 20
Rating date
Live price in the app →
Quality63
Momentum58
Risk-adjusted55
Source basis SEC filings and live market dataDated snapshot

About Pfizer Inc.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. Once a maker of many types of healthcare products and chemicals, it now derives most sales from prescription drugs and vaccines, with top sellers including the pneumococcal vaccine Prevnar 13 and the cardiology drugs Vyndaqel and Eliquis; it sells globally, with international sales 40% of the total and emerging markets a major contributor.

Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How PFE's rating has moved

  • 0Past week, since Nov 13: score held at 63.
  • -1Past two weeks, since Nov 6: no longer flagged Runner!, now Hold, score fell 1 point to 63.

Weekly points: Nov 6: 64 · Nov 13: 63 · Nov 20: 63 (this page).

From MELANY's own dated rating record. A tier change is reported as a move between named tiers; the score carries the direction.

Why PFE scores 63/100

PFE's 8 factor scores run from 36 to 93, and 1 of them sits above its composite of 63. Here is how PFE breaks down.

Valuation61/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

  • Forward P/E 9.3x, earnings growth accelerating
  • FCF yield 7.5%
Business quality63/100

Margins, returns on capital, and balance-sheet strength.

  • Gross margin 73%
Price momentum58/100

Direction and relative strength of the recent share-price trend.

  • 50-day MA above 200-day (golden cross zone)
Earnings track record93/100

History of beating or missing estimates, and where estimates are heading.

  • Beat EPS estimates 4 of last 4 quarters
  • Avg EPS beat +12%
Analyst sentiment62/100

What Wall Street price targets and revisions are signalling.

Catalyst setup36/100

Near-term events that could move the stock.

Risk-adjusted profile55/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

How PFE compares

As of November 20, 2026, Pfizer Inc. is tied for 8th of 20 in Healthcare Stocks, where the average score is 62.

All stock rating pages.

Key risks for PFE

  • Performance partly driven by Healthcare sector, rotation away from this theme would hurt

Sector and theme context

Pfizer Inc. sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds PFE's momentum and catalyst factors above.

Tracking PFE

Pfizer Inc. rates Hold right now, so MELANY is not flagging a fresh entry. Add PFE to a watchlist in the app to follow its rating; an alert the moment it changes is part of Pro, free for 30 days.

How MELANY rates PFE

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Pfizer Inc.'s 63/100 reflects mature factor weighting for its profile.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about PFE

Is Pfizer Inc. (PFE) a buy?

As of 2026-11-20, MELANY rated Pfizer Inc. Hold with a composite score of 63/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

How has PFE's rating changed recently?

As of 2026-11-20, MELANY scores PFE 63/100 (Hold); a week earlier (Nov 13) it was 63, 2 weeks earlier (Nov 6) it was 64. These points come from MELANY's own dated rating record.

How does PFE rank against similar companies?

As of November 20, 2026, Pfizer Inc. is tied for 8th of 20 in MELANY's Healthcare Stocks list, where the average score is 62. Among the other names in the list, the highest scores belong to REGN (74) and MDT (71).

Should I buy Pfizer Inc. stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Pfizer Inc. (PFE) Hold with a composite of 63/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the PFE stock price forecast?

MELANY does not publish price targets or forecasts for PFE. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 63/100 across eight factors for Pfizer Inc., and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for PFE as of 2026-11-20: its analyst sentiment factor is 62/100, and its price momentum factor is 58/100.

Is PFE stock overvalued or undervalued?

MELANY's valuation factor currently reads 61/100 for Pfizer Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives PFE's read.

What price should I buy PFE at?

MELANY is not flagging a fresh entry for PFE at its current Hold rating, so there is no entry zone to publish right now. Add PFE to a watchlist in the app to follow it; an alert the moment the rating changes is part of Pro, free for 30 days.

What are the risks of buying PFE stock?

The top risks MELANY currently flags for Pfizer Inc.: Performance partly driven by Healthcare sector, rotation away from this theme would hurt. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is Pfizer Inc. a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 63/100 for Pfizer Inc., and earnings track record, at 93/100. The 63/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will PFE stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 58/100 for PFE right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this PFE rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores PFE as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, PFE included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.